

Index

acetylcholine, 102	parasympathetic dysfunction, 56–58	cognitive decline and dementia
Alzheimer disease, 52, 80	sympathetic dysfunction, 56	genetics
amantadine, 190		familial genes, 201–202
animal models, 5–9		<i>GBA</i> variants, 202
antipsychotics for cognitive dysfunction, 73–74	basal cell carcinoma, 193	prevalence of, 80
anxiety	BDNF gene, 202	cognitive dysfunction
assessment tools, 22	Beck Depression Inventory-II (BDI-II), 23	clinical presentation, 69–71
cognitive dysfunction symptoms, 72–73	bent spine syndrome, 178–179	clinical risk factors for, 67–68
genetics, 203	Berlin Questionnaire, 171	dementia neuropathology, 40
impulsive-compulsive disorders (ICDs), 229	binge eating, 226, 227–228	etiology of, 66–67
apathy	biomarkers	genetics, 68
assessment tools, 23	mild cognitive impairment in Parkinson’s disease (MCI-PD), 63	pathogenesis, 68–69
clinical presentation, 82–83	neuropathology, 42	prevalence of, 66, 79–80
impulsive-compulsive disorders (ICDs), 228–229	non-motor symptoms (NMS), 11–12	cognitive dysfunction management
treatment, 83	PET and SPECT neuroimaging, 47	nonpharmacologic, 73
apathy scale (AS), 23	Braak stages, 38–40	pharmacologic, 73–74, 80–81
<i>APOE</i> gene	bradykinesia, 67	cognitive dysfunction
cognitive decline and dementia	bullous pemphigoid (BP), 192–193	neuroimaging
genetics, 202		Alzheimer pathology, 51–52
hallucinations, 203	camptocormia, 178–179	cholinergic changes, 50–51
Apomorphine skin lesions, 191	cardiovascular dysfunction	dopamine dysfunction, 49–50
Apomorphine treatment, 160	autonomic system, 130–133	glucose metabolic changes, 48–49
Ardouin Scale of Behavior in Parkinson’s disease (ASBPd), 23	supine hypertension, 132	microglia inflammation, 52
autonomic dysfunction	symptoms, 130–132	structural changes, 48, 69
assessment tools, 21–22	cardiovascular dysfunction management	types of, 46–48
cardiovascular, 130–133	lifestyle treatments for, 132	cognitive dysfunction symptoms
cognitive dysfunction, 67	medication review, 132–133	anxiety, 72–73
drug-induced, 218–219	caregiver burden in late-stage Parkinson’s disease, 31	attention, 71
enteric nervous system (ENS), 135	“cheese reaction”, 248	construction, 72
fluctuations, 10	cholinergic changes	delusions, 72
gastrointestinal, 136–137	functional imaging for, 54	depression, 72–73
genetics and, 204	neuroimaging for, 50–51	executive functions, 72
non-motor fluctuations (NMF), 220	cholinergic pathway and cognitive dysfunction, 69	hallucinations, 72
oropharyngeal, 135–136	cholinesterase inhibitors for cognitive impairment	language, 72
sexual, 141–143	donepezil, 73	memory, 71–72
sweating dysfunction, 189–190	memantine, 73	praxis, 72
thermoregulation, 133–134	rivastigmine, 73	severity of, 68
urinary, 137–141	classical orthostatic hypotension, 131	sleep disorders, 73
vision, 134–135	clozapine, 85, 103–104	vision impairment, 119
weight loss, 135	cognitive behavioral therapy (CBT), 95	visual perception, 72
autonomic dysfunction neuroimaging studies		<i>COMT</i> gene
		cognitive decline and dementia
		genetics, 202
		pain, 204
		constipation, 136–137, 148–149
		corticobasal syndrome (CBS), 120–121

Index

- cutaneous manifestations of
 - Parkinson's disease
 - bullous pemphigoid (BP), 192–193
 - cancers, 193–194
 - perioral dermatitis, 189
 - rosacea, 188–189
 - seborrheic dermatitis (SD), 187–188
 - skin lesions from deep brain stimulation (DBS), 191–192
 - sweating dysfunction, 189–190
- cutaneous manifestations of Parkinson's disease, drug-induced
 - amantadine-induced livedo reticularis, 190
 - Apomorphine injections, 191
 - levodopa-carbidopa intestinal gel (LCIG) treatment, 191
 - Rotigotine application site reaction, 190–191
- DDC gene variants, 204
- deep brain stimulation (DBS)
 - defined, 96
 - eye movements, 121
 - sexual dysfunction, 159
 - skin lesions from, 191–192
 - vestibular function and balance, 121–122
- delayed orthostatic hypotension, 131–132
- dementia
 - occurrence in PD, 46
 - prevalence of, 80
- dementia with Lewy bodies (DLB)
 - neuroimaging, 49
 - Parkinson's disease, 62
- depression
 - assessment tools, 23
 - cognitive dysfunction symptoms, 72–73
 - epidemiology, 91
 - genetics, 203
 - impulsive-compulsive disorders (ICDs), 228, 229
 - mood agents for, 74
 - neuropathology of, 40
 - pathophysiology of, 91–92
 - psychiatric symptoms, 81–82
 - symptoms and diagnosis, 92–93
- depression, neuroimaging studies
 - brain structure changes, 52
 - functional imaging changes, 53–54
- depression management
 - neurostimulation, 95–96
 - pharmacology, 93–95
 - psychotherapies, 95
- donepezil, 73, 81
- dopamine
 - assessment tools, 23
 - functional imaging for, 53
 - impulse control disorders (ICDs), 10
 - impulsive-compulsive behaviors, 231–232
 - neuroimaging for, 49–50
 - non-motor symptoms (NMS), 10
 - olfactory dysfunction, 102
- dopamine dysregulation syndrome, 87, 226, 228, 233
- drug-induced Parkinson's disease (DIP)
 - non-motor symptoms (NMS), 213
 - olfactory dysfunction, 103–104
 - Parkinson's disease (PD)
 - psychosis, 212–216
- dyspareunia, 161
- dysphagia, 135–136, 146–147
- electroconvulsive therapy (ECT), 96
- enteric nervous system (ENS)
 - as autonomic dysfunction, 135
 - gastrointestinal dysfunction, 149
- Epworth Sleepiness Scale (ESS), 168
- erectile dysfunction, 161
- essential tremor (ET), 104
- excessive daytime sleepiness (EDS)
 - assessment tools, 168
 - clinical presentation, 167
 - defined, 167
 - drug-induced, 216–218
 - epidemiology, 167
 - genetics, 201
 - management, 168
 - neuroimaging for, 54–55
 - pathophysiology of, 167
 - pharmacology, 169
 - sleep agents for, 74
- exercise therapy, 95
- familial Parkinson's disease, 104–107. *see also* genetics in Parkinson's disease
- fatigue
 - assessment, 22, 23, 83
 - neuroimaging for, 54
 - treatment, 83–84
- Fatigue Severity Scale (FSS), 22, 23
- frozen shoulder syndrome, 180
- Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT), 22, 23
- functional imaging in non-motor symptoms (NMS)
 - cholinergic changes, 54
 - dopamine function, 53
 - noradrenergic dysfunction, 54
 - serotonergic function, 53–54
- gambling, compulsive, 225–226
- gastrointestinal dysfunction
 - as autonomic dysfunction, 136
 - constipation, 136–137, 148–149
 - dysphagia, 146–147
 - enteric nervous system (ENS), 149
 - gastric emptying, 147–148
 - microbiome genetics, 150–151
 - sialorrhea, 145–146
 - small intestinal bacterial overgrowth syndrome (SIBO), 136
- Gaucher's disease, 107
- GBA variants
 - autonomic dysfunction, 204
 - cognitive decline and dementia genetics, 202
 - depression, 203
 - hallucinations, 203
 - olfactory function, 204
- genetics in Parkinson's disease. *see also* familial Parkinson's disease
 - autonomic dysfunction, 204
 - background of, 199
 - cognitive decline and dementia, 68, 201–203
 - impulsive-compulsive disorders (ICDs), 229
 - insomnia, 201
 - microbiome, 150–151
 - olfactory function, 204
 - pain, 204
 - psychiatric symptoms, 203–204
 - rapid eye movement (REM) sleep behavior disorder (RBD), 199–200
 - restless legs syndrome (RLS), 201
 - sleep disorders, 199–201
- hallucinations
 - cognitive dysfunction, 72
 - genetics, 203
- Hamilton Depression Scale (Ham-D), 23
- health-related quality of life (HRQoL), 31–32
- hypersalivation, 135
- hyposmia, 56–58
- impulsive-compulsive behaviors
 - assessment tools, 23
 - binge eating, 226
 - defined, 86, 225
 - dopamine dysregulation syndrome (DDS), 226
 - gambling, 225–226
 - genetics, 203–204
 - history of, 224–225
 - pharmacotherapy, 86–87

- punding, 226
- sexual, 225
- shopping, 226
- impulsive-compulsive disorders (ICDs)
 - assessment tools, 229
 - background of, 227
 - dopamine-induced, 10
 - genetics, 229
 - pathophysiology of, 229–233
 - psychiatric comorbidities, 228–229
 - risk factors for, 227–228
- impulsive-compulsive disorder (ICD) imaging techniques
 - case studies, 233
 - dopamine, 231–232
 - follow-up, 234–235
 - management, 233–234
 - MRI studies, 229–230
 - multimodal, 231
 - PET studies, 230–231
- initial orthostatic hypotension, 130
- insomnia
 - assessment tools, 168
 - clinical presentation, 168
 - defined, 168
 - epidemiology, 168
 - genetics, 201
 - management, 168
 - pathophysiology of, 168
- King's Parkinson's Disease Pain Scale (KPPS), 20–21
- levodopa-carbidopa intestinal gel (LCIG) treatment, 160
- levodopa-carbidopa intestinal gel, skin lesions from, 191
- levodopa, 119, 218
- Lewy body disease
 - clinical presentation, 69–71
 - cognitive dysfunction, 68–69
 - gastrointestinal dysfunction, 149
 - most studied features of, 35
 - neural asymmetry, 41
 - olfactory dysfunction, 101
 - pathophysiology of, 38
- livedo reticularis (LR), 190
- LRRK2* mutations
 - cognitive decline and dementia
 - genetics, 201–202
 - olfactory function and, 204
- MAPT* gene, 202
- melanoma, 193–194
- memantine, 73, 81
- microglia inflammation, 52
- mild cognitive impairment in Parkinson's disease (MCI-PD)
 - biomarkers, 63
 - difficulty in diagnosing, 62–63
 - investigations, 64
 - management, 64
 - prevalence of, 62
 - therapy, 63
- mild cognitive impairment (MCI), 79
- mindfulness therapy, 95
- monoamine oxidase inhibitors (MAOIs)
 - history, 241
 - MAO-B issues, 247–248
 - role in physiology, 241
 - serotonin syndrome, 243–247
 - treatment evidence, 241–243
- monoamine oxidase inhibitors (MAOIs) cardiovascular complications
 - “cheese reaction”, 248
 - mortality, 248
 - orthostatic hypotension (OH), 248
- Montgomery-Asberg Depression Rating Scale (MADRS), 23
- motor and non-motor symptoms, 242
- Movement Disorder Society – non-motor symptoms scale (MDS-NMS)
 - development of, 3
 - symptoms covered and features, 4
- Movement Disorder Society – non-motor symptoms Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (MDS-NMS), 4
- Movement Disorder Society – Unified Parkinson's Disease Rating Scale (MDS-UPDRS), 20
- Multidimensional Fatigue Inventory (MFI), 23
- multiple sleep latency test (MSLT), 168
- multiple system atrophy (MSA)
 - olfactory dysfunction, 108
 - vision, 119–120
- Multivariable Apnea Prediction (MAP) Index, 171
- musculoskeletal disorders
 - camptocormia, 178–179
 - osteoporosis, 179–180
 - Pisa syndrome, 179
 - posture studies, 178
 - prevalence of, 178
 - shoulder and elbow, 180
- nausea, drug-induced
 - management, 218–219
 - prevalence of, 218
- neurogenic orthostatic hypotension (nOH), 131
- neuroimaging in non-motor systems (NMS) Parkinson's
 - for autonomic denervation, 56–58
 - for cognitive impairment, 46–52
 - for depression, 52–54
 - for fatigue, 54
 - PET and SPECT biomarkers, 47
 - for sleep disorders, 54–56
- neuroleptic malignant syndrome (NMS), 244
- neuropathology criteria in Parkinson's disease
 - abnormal α -synuclein, 35–37
 - clinical features beyond staging systems, 40–41
 - Lewy neurites and bodies, 35–37
 - peripheral nervous system, 38–40
 - staging of α -synucleinopathies, 37–38
- neuropathology in Parkinson's disease
 - future directions for, 41–42
 - motor and non-motor symptoms, 35
- neuropsychiatric fluctuations
 - assessment tools, 22–23
 - in Parkinson's disease, 9
- Neuropsychiatric Inventory (NPI), 23
- neurotransmitter/neuromodulator system (NT/NM), 102–103
- non-dopaminergic systems in Parkinson's disease, 11
- non-motor fluctuations (NMF)
 - autonomic dysfunction, 220
 - diagnosis, 220
 - management, 220–221
 - in Parkinson's disease, 9
 - pathophysiology of, 220
 - psychiatric symptoms, 219
 - sensory symptoms, 220
 - treatment, 12–13
- Non-Motor Symptoms Questionnaire (NMSQuest), 18–19
- Non-Motor Symptoms Scale (NMSS), 19–20
- non-motor symptoms (NMS)
 - autonomic fluctuations, 9, 10
 - defined, 3
 - digitalized measurements for, 5
 - dopamine-induced, 10
 - drug-induced, 219–221
 - gender, 5
 - genetics, 205
 - holistic scales for non-motor measurements, 3–4
 - monoamine oxidase inhibitors (MAOIs), 242
 - neuroimaging for, 46–58
 - neuropathology, 35–42
 - neuropsychiatric fluctuations, 9
 - pain fluctuations, 10
 - in palliative phase of Parkinson's disease, 5

Index

- non-motor symptoms (cont.)
 - subgroup studies, 5
 - symptoms, 3
 - treatment, 12
 - non-motor symptoms (NMS) early stage
 - assessment tools summary, 18
 - autonomic dysfunction
 - assessment, 21–22
 - fatigue assessment, 22
 - holistic scales for non-motor measurements, 18–20
 - neuropsychiatric assessment, 22–23
 - pain assessment, 20–21
 - sleep assessment, 21
 - non-motor symptoms (NMS) in late-stage Parkinson's disease
 - epidemiology, 27–31
 - management difficulty, 27
 - most bothersome complaints, 28
 - quality of life with, 31–32
 - Non-Motor Symptoms Questionnaire (NMSQ)
 - development of, 3
 - for late-stage Parkinson's disease, 27, 28–29
 - Non-Motor Symptoms Scale (NMSS)
 - development of, 3
 - symptoms covered and features, 4
 - norepinephrine, 102–103
 - obstructive sleep apnea (OSA)
 - assessment tools, 171
 - clinical presentation, 171
 - defined, 171
 - epidemiology, 171
 - management, 171
 - pathophysiology of, 171
 - olanzapine, 85, 103–104
 - olfactory dysfunction
 - essential tremor (ET), 104
 - familial Parkinson's disease, 104–107
 - Gaucher's disease, 107
 - genetics, 204
 - importance of smell loss, 99
 - multiple system atrophy (MSA), 108
 - neuroimaging for, 56–58
 - Parkinson's dementia complex of Guam, 108–109
 - prevalence of, 99
 - rapid eye movement, 107–108
 - vascular Parkinson's disease, 109
 - olfactory dysfunction in classic Parkinson's disease
 - olfactory phenotype, 99–100
 - system pathology, 100–103
 - olfactory dysfunction in drug-induced Parkinson's disease, 103–104
 - olfactory neuroepithelium
 - pathology
 - central structures, 101–102
 - Lewy bodies and neurites, 101
 - neurotransmitter/neuromodulator system (NT/NM), 102–103
 - oropharyngeal dysfunction
 - dysphagia, 135–136
 - hypersalivation, 135
 - orthostatic hypotension (OH)
 - 24-hour ambulatory blood pressure monitoring, 130
 - classical, 131
 - clinical presentation, 218
 - delayed, 131–132
 - frequency of, 131
 - initial, 131
 - lifestyle treatments for, 132
 - management, 218
 - monoamine oxidase inhibitors (MAOIs), 248
 - neurogenic, 131
 - standing test, 130
 - symptomatic/asymptomatic form, 132
 - tilt table assessment, 130
- osteoporosis, 179–180
 - otolith function, 122–123
 - pain in Parkinson's disease
 - assessment tools, 20–21
 - classification, 181–182
 - frequency of, 180
 - genetics, 204
 - management, 183–184
 - in Parkinson's disease, 10
 - pathophysiology of, 182–183
 - types of, 180–181
 - parasympathetic dysfunction
 - neuroimaging, 56–58
 - PARK mutation and anxiety, 203
 - Parkinson Anxiety Scale (PAS), 22
 - Parkinson Fatigue Scale – 16 item (PFS-16), 22, 23
 - Parkinson Psychosis Questionnaire (PPQ), 23
 - Parkinson's dementia complex of Guam, 108–109
 - Parkinson's disease (PD)
 - cognitive dysfunction in, 66–74
 - Gaucher's disease, 107
 - mild cognitive (MCI) impairment in, 62–64
 - multiple system atrophy (MSA), 108, 119–120
 - non-motor symptoms (NMS)
 - early stage, 18–24
 - non-motor symptoms (NMS)
 - genetics, 199–204
 - non-motor symptoms (NMS) in late-stages, 27–32
 - non-motor symptoms (NMS)
 - neuroimaging studies, 46–58
 - non-motor symptoms (NMS) neuropathology, 35–42
 - Parkinson's dementia complex of Guam, 108–109
 - pregnancy, 252–253
 - vascular, 109
 - Parkinson's disease (PD) overview
 - non-dopaminergic systems, 11
 - non-motor symptoms (NMS)
 - biomarkers, 11–12
 - non-motor symptoms (NMS)
 - burden, 3–5
 - non-motor symptoms (NMS)
 - defined, 3
 - non-motor symptoms (NMS) in animal models, 5–9
 - treatment, 12–13
 - Parkinson's disease (PD) psychosis.
 - see also* psychosis
 - classification scales, 214–215
 - defined, 212–216
 - diagnosis, 214
 - management, 216
 - pathophysiology of, 215
 - phenomenology of, 212–214
 - prevalence of, 212
- perioral dermatitis, 189
 - peripheral nervous system
 - neuropathology, 38–40
 - pervasive ocular tremor, 124–126
 - pharmacology
 - excessive daytime sleepiness (EDS), 169
 - monoamine oxidase inhibitors (MAOIs), 241–248
 - sexual dysfunction, 158–159
 - pimavanserin, 86
 - PINK1 mutations
 - anxiety, 203
 - cognitive decline and dementia
 - genetics, 202
 - depression, 203
 - impulsive-compulsive behaviors, 203
 - Pisa syndrome, 179
 - pregnancy and Parkinson's disease, 252–253
 - premature ejaculation treatment, 161
 - PRIAMO (Parkinson and non-motor symptoms) study, 29
 - PRKN mutations
 - autonomic dysfunction, 204
 - cognitive decline and dementia
 - genetics, 202
 - impulsive-compulsive behaviors, 203
 - olfactory function, 204
 - progressive supranuclear palsy (PSP), 120

- psychiatric symptoms
 - apathy, 82–83
 - cognitive dysfunction, 79–81
 - depression, 81–82
 - fatigue, 83–84
 - impulsive-compulsive behaviors, 86–87
 - non-motor fluctuations (NMF), 219
 - pathophysiology of, 78–79
 - psychosis, 84–86
 - types of, 78
- psychiatric symptoms and genetics
 - anxiety, 203
 - depression, 203
 - hallucinations, 203
 - impulsive-compulsive behaviors, 203–204
- psychodynamic therapy, 95
- psychosis. *see also* Parkinson's disease (PD) psychosis
 - cognitive dysfunction, 80
 - defined, 84
 - pathogenesis, 84
 - pharmacotherapy algorithm, 84–86
 - prevalence of, 84
- psychosis assessment tools, 23
- punding, 226, 228
- Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease (QUIP), 23
- quetiapine, 85–86, 103–104
- rapid eye movement (REM) sleep
 - behavior disorder (RBD)
 - assessment tools, 172
 - clinical presentation, 172
 - cognitive dysfunction, 67–68
 - defined, 171
 - epidemiology, 171
 - genetics, 199–200
 - management, 172–173
 - neuroimaging for, 55–56
 - neuropathology of, 40
 - olfactory dysfunction, 107–108
 - pathophysiology of, 172
 - sleep agents for, 74
- restless legs syndrome (RLS)
 - assessment tools, 170
 - clinical presentation, 170
 - defined, 170
 - epidemiology, 170
 - genetics, 201
 - management, 170–171
 - pathophysiology of, 170
- Richardson syndrome. *see* progressive supranuclear palsy
- risperidone, 85, 103–104
- rivastigmine, 73, 81
- rosacea, 188–189
- Rotigotine, 190–191
- saccades
 - background of, 115
 - cerebral control of, 115–117
 - cognitive impairment, 119
 - laboratory eye movement findings, 117–119
- Scales for Outcomes in Parkinson's disease (SCOPA), 21, 23
- Schedule for Assessment of Positive Symptoms (SAPS), 23
- SCN9A variants, 204
- SCOPA-Autonomic (SCOPA-AUT) scale, 21–22
- seborrheic dermatitis (SD), 187–188
- sensory dysfunction and non-motor fluctuations (NMF), 220
- Serious Games, 162
- serotonin
 - functional imaging for, 53–54
 - olfactory dysfunction, 102–103
- serotonin norepinephrine reuptake inhibitors (SNRIs), 93–95
- serotonin reuptake inhibitors (SSRIs), 93–95
- serotonin syndrome
 - clinical presentation, 243–244
 - diagnosis, 244–247
 - drugs implicated in, 244
 - management, 247
 - in Parkinson's disease, 243
 - pathophysiology of, 243
- sexual dysfunction
 - as autonomic dysfunction, 141–143
 - background of, 155
 - compulsive behavior, 225, 227–228
 - effect on partner's sexuality, 160
 - epidemiology, 155
 - in men, 157
 - sexual function changes, 155–156
 - sexual response cycle, 156
 - in women, 156
- sexual dysfunction treatment
 - Apomorphine, 160
 - deep brain stimulation (DBS), 159
 - doctor–patient discussion, 160–161
 - levodopa-carbidopa intestinal gel (LCIG), 160
 - modalities, 161–162
 - pharmacology, 158–159
 - Serious Games, 162
 - virtual reality, 162
- sexual preoccupation behaviors (SPBs)
 - symptoms, 157–158
 - treatment, 162
- shopping, compulsive, 226, 227–228
- sialorrhea, 145–146
- sleep and the Parkinson's Disease Sleep Scale (PDSS), 21
- sleep and the Parkinson's Disease Sleep Scale Revised (PDSS-2), 21
- sleep disorders
 - drug-induced, 216–218
 - excessive daytime sleepiness (EDS), 167–168
 - insomnia, 168
 - neuroimaging for, 54–56
 - neuropathology of, 39–40
 - obstructive sleep apnea (OSA), 171
 - rapid eye movement (REM) sleep behavior disorder (RBD), 171–173
 - restless legs syndrome (RLS), 170–171
- sleep disorders and genetics
 - excessive daytime sleepiness (EDS), 201
 - insomnia, 201
 - rapid eye movement (REM) sleep behavior disorder (RBD), 199–200
 - restless legs syndrome (RLS), 201
- sleep disorders assessment tools, 21
- small intestinal bacterial overgrowth syndrome (SIBO), 136
- smooth pursuit eye movements, 116, 119
- SNCA mutations
 - autonomic dysfunction, 204
 - cognitive decline and dementia genetics, 201
 - depression, 203
 - olfactory function, 204
- Stanford Sleepiness Scale (SSS), 168
- STOP-Bang Questionnaire, 171
- supine hypertension
 - in cardiovascular dysfunction, 132
 - lifestyle treatments for, 132
- sweating dysfunction, 189–190
- sympathetic dysfunction
 - neuroimaging, 56
- testosterone insufficiency
 - treatment, 161
- thermoregulation dysfunction, 133–134
- transcranial magnetic stimulation (TMS), 96
- tricyclic antidepressants (TCAs), 93–95
- urinary dysfunction, 137–141

Index

vascular Parkinson’s disease, 109	in multiple system atrophy, 119–120	visuo-vestibular interaction, 122–124
virtual reality, 162	ocular dyskinesia, 119	visuo-vestibular interaction multi-sensory integration, 123–124
vision	in progressive supranuclear palsy (PSP), 120	otolith function, 122–123
clinical presentation, 116–117	pupillo-motor and tear regulation, 134–135	pervasive ocular tremor, 124–126
cognitive dysfunction, 72	saccades, 115–117	
corticobasal syndrome (CBS), 120–121	smooth pursuit eye movements, 116	weight loss, 135
deep brain stimulation (DBS), 121–122	underlying neural mechanisms for, 115–116	yoga therapy, 95
laboratory eye movement findings, 117–119		